A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, First-in-human Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Single Ascending Oral Doses Of Pf-06852231 Administered To Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2017
At a glance
- Drugs PF-06852231 (Primary)
- Indications Neurological disorders
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 22 Sep 2017 Planned End Date changed from 15 Dec 2017 to 8 Mar 2018.
- 22 Sep 2017 Planned primary completion date changed from 15 Dec 2017 to 8 Mar 2018.
- 01 Aug 2017 Status changed from not yet recruiting to recruiting.